![origenis_logo_Pantone [Konvertiert]_2020](https://static.wixstatic.com/media/9afeac_83ea95f8f63144538d48a310b96d7f33~mv2.png/v1/fill/w_260,h_53,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/origenis_logo_Pantone%20%5BKonvertiert%5D_2020.png){kind=logo}
Collaborations
where no one has gone before
Collaborate with us
The Company’s scalable AI platform
The Company's scalable AI platform designs novel chemical matter and optimizes them in a repeatedly proven process towards high-quality preclinical development candidates (PDCs).
After performing services for others, Origenis built a portfolio of 5 projects in the neurodegeneration field with LRRK2 as lead program, which now is being developed in a new US-based company.
​
Building on this success, we are planning to repeat the creation of new portfolios based on related targets with the focus on small molecules crossing the blood brain barrier.
​
We plan to spin these portfolios out into new companies which will be financed and staffed for indication focused development.
​
Additionally, we collaborate with research entities bringing disease relevant biology complementing our effective small molecule discovery and development platform.
​
We also do selective research collaborations, specifically in areas that help improving our technologies and platform.
​
Business Model for Investors
